ARID1A and ovarian carcinoma: Several other molecular biological therapies have emerged for the treatment of ovarian cancer with mutations in the SWI/SNF complex subunits ARID1A and SMARCA4, mainly divided into the following categories: (1) epigenetic synthetic lethality; (2) activation of the pro‐apoptotic effect of wild‐type p53; (3) checkpoint blockade immunotherapy; (4) DNA damage signalling inhibitors; (5) cellular kinase signalling pathways.70